In vitro and in vivo activities of sedecamycin against Treponema hyodysenteriae.
Sedecamycin (lankacidin A), one of the lankacidin-group antibiotics, showed potent activity against Treponema hyodysenteriae. The MICs of sedecamycin against 79 field isolates of T. hyodysenteriae ranged from 0.78 to 12.5 micrograms/ml, the MIC for 90% of the strains tested (MIC90) being 3.13 micrograms/ml. The protective and therapeutic effects of sedecamycin were compared with those of carbadox, tiamulin, and lincomycin against experimental infection with T. hyodysenteriae in mice. The protective effect of sedecamycin was similar to that of carbadox, two times more potent than that of tiamulin, and three times greater than that of lincomycin. In the therapeutic test, sedecamycin showed activity similar to that of carbadox and was two times more active than both tiamulin and lincomycin. At doses of 10 mg or more of sedecamycin per kg, the recurrence of shedding of T. hyodysenteriae into the feces of mice was not detected for at least 8 weeks postmedication.
Hayashi
T
T
Animal Health Products Division, Takeda Chemical Industries, Ltd., Osaka, Japan.
Suenaga
I
I
Narukawa
N
N
Yamazaki
T
T
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology / Q000627:therapeutic use; D002218:Carbadox / Q000627:therapeutic use; D004224:Diterpenes / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005243:Feces / Q000382:microbiology; D005260:Female; D008034:Lincomycin / Q000627:therapeutic use; D018942:Macrolides; D051379:Mice; D014208:Treponema / Q000187:drug effects* / Q000302:isolation & purification; D014209:Treponema Immobilization Test; D014211:Treponemal Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D001643:Bridged Bicyclo Compounds; D004224:Diterpenes; D018942:Macrolides; D008034:Lincomycin; C014224:tiamulin; D002218:Carbadox; C054134:sedecamycin